Drug intelligence / Profile preview

D-28P001

Development stage: Preclinical
Lead developer: Gilead Sciences
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

D-28P001 is a novel aptamer developed by Drive Therapeutics, LLC. It is currently in the discovery phase for the treatment of various retinal diseases, including diabetic macular oedema, retinal vein occlusion, and wet age-related macular degeneration. As an aptamer, it is a single-stranded nucleic acid molecule designed to bind to specific targets, thereby inhibiting their function. The drug is being developed as an inhibitor of angiogenesis and inflammation, processes that are central to the pathology of these ocular conditions.

Beyond the preview

Go deeper on D-28P001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-28P001.

Explore the full profile